Patients were treated with adalimumab and evaluated for up to 148weeks as 3 data cohorts : the all-adalimumab cohort ( patients receiving 1 injection of adalimumab ) , the 148-week follow-up subcohort ( patients who completed 148weeks of follow-up after the first adalimumab dose ) , and the dose-escalation subcohort ( patients receiving adalimumab doses that increased to 80mg every other week ) .